Caligan Partners
$2.1B 13F equity value
30 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Caligan Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| LQDA | LIQUIDIA CORPORATION | 8,118,892 | $647M | 31.2% |
| RVMD | REVOLUTION MEDICINES INC | 1,961,795 | $367M | 17.7% |
| ABVX | ABIVAX SA | 1,557,924 | $208M | 10.0% |
| PCVX | VAXCYTE INC | 2,188,636 | $127M | 6.1% |
| EXEL | EXELIXIS INC | 1,553,262 | $85M | 4.1% |
| TNGX | TANGO THERAPEUTICS INC | 2,500,103 | $78M | 3.8% |
| AVTX | AVALO THERAPEUTICS INC | 3,163,866 | $58M | 2.8% |
| XENE | XENON PHARMACEUTICALS INC | 889,944 | $54M | 2.6% |
| ADMA | ADMA BIOLOGICS INC | 5,725,007 | $48M | 2.3% |
| LBRX | LB PHARMACEUTICALS INC | 1,438,070 | $47M | 2.3% |
Track Caligan Partners's 13F portfolio: $2.1B in reported holdings, 30 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}